TWI250978B - New compounds - Google Patents
New compounds Download PDFInfo
- Publication number
- TWI250978B TWI250978B TW092104743A TW92104743A TWI250978B TW I250978 B TWI250978 B TW I250978B TW 092104743 A TW092104743 A TW 092104743A TW 92104743 A TW92104743 A TW 92104743A TW I250978 B TWI250978 B TW I250978B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- formula
- compound
- alkyl
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 73
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 39
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract 2
- -1 boil Chemical compound 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 36
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 34
- 229910052731 fluorine Chemical group 0.000 claims description 34
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 28
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 125000005504 styryl group Chemical group 0.000 claims description 24
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 22
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 17
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 16
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 150000002923 oximes Chemical class 0.000 claims description 16
- 239000007789 gas Substances 0.000 claims description 15
- 150000004032 porphyrins Chemical class 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims description 12
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 12
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 12
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 12
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 11
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 11
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 claims description 10
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 10
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 10
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 9
- 150000004677 hydrates Chemical class 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 7
- 239000011677 pyridoxine Substances 0.000 claims description 7
- 235000008160 pyridoxine Nutrition 0.000 claims description 7
- 229940011671 vitamin b6 Drugs 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 claims description 3
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- 229960000948 quinine Drugs 0.000 claims description 2
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000004953 trihalomethyl group Chemical group 0.000 claims 5
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 150000002429 hydrazines Chemical class 0.000 claims 2
- QQBPIHBUCMDKFG-UHFFFAOYSA-N phenazopyridine hydrochloride Chemical class Cl.NC1=NC(N)=CC=C1N=NC1=CC=CC=C1 QQBPIHBUCMDKFG-UHFFFAOYSA-N 0.000 claims 2
- 150000003212 purines Chemical class 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 claims 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 claims 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims 1
- MJMABLVPJALRQA-UHFFFAOYSA-N CN(C#N)[N+](=O)[S-] Chemical compound CN(C#N)[N+](=O)[S-] MJMABLVPJALRQA-UHFFFAOYSA-N 0.000 claims 1
- NAEKXNBPQGUGCK-UHFFFAOYSA-N CN1N=NC=NN=N1 Chemical compound CN1N=NC=NN=N1 NAEKXNBPQGUGCK-UHFFFAOYSA-N 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- 244000028419 Styrax benzoin Species 0.000 claims 1
- 235000000126 Styrax benzoin Nutrition 0.000 claims 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 1
- 235000008411 Sumatra benzointree Nutrition 0.000 claims 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical group NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims 1
- 229960002130 benzoin Drugs 0.000 claims 1
- 238000007664 blowing Methods 0.000 claims 1
- 235000019382 gum benzoic Nutrition 0.000 claims 1
- YRBKSJIXFZPPGF-UHFFFAOYSA-N hexazine Chemical class N1=NN=NN=N1 YRBKSJIXFZPPGF-UHFFFAOYSA-N 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 claims 1
- 238000003971 tillage Methods 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 55
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000002844 melting Methods 0.000 description 20
- 230000008018 melting Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HMOQPOVBDRFNIU-UHFFFAOYSA-N barium(2+);dioxido(oxo)silane Chemical compound [Ba+2].[O-][Si]([O-])=O HMOQPOVBDRFNIU-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- CBZSXVKRXDBDFV-UHFFFAOYSA-K C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Bi+3].[Ba+2] Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Bi+3].[Ba+2] CBZSXVKRXDBDFV-UHFFFAOYSA-K 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 6
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- YXXXFTZMJKUYSM-UHFFFAOYSA-H 5-hydroxy-2,8,9-trioxa-1-bismabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Bi+3].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YXXXFTZMJKUYSM-UHFFFAOYSA-H 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 229940006612 barium citrate Drugs 0.000 description 3
- ODRYQKTVJMBLFK-UHFFFAOYSA-L barium(2+);tridecanoate Chemical compound [Ba+2].CCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCC([O-])=O ODRYQKTVJMBLFK-UHFFFAOYSA-L 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OXNYRQCAMIFHEM-UHFFFAOYSA-K C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Sr+2].[Ba+2] Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Sr+2].[Ba+2] OXNYRQCAMIFHEM-UHFFFAOYSA-K 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000004970 halomethyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- USMNOWBWPHYOEA-XKSSXDPKSA-N (+)-beta-thujone Chemical compound O=C([C@H]1C)C[C@@]2(C(C)C)[C@@H]1C2 USMNOWBWPHYOEA-XKSSXDPKSA-N 0.000 description 1
- AEFBNJXWRHSZGO-UHFFFAOYSA-N 1,2,3,3a,4,5-hexahydropyrene Chemical compound C1=C2CCCC(CC3)C2=C2C3=CC=CC2=C1 AEFBNJXWRHSZGO-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- SSKBPPNEPSALEP-UHFFFAOYSA-N 1-fluoropyrrolidine-2-carbonitrile Chemical compound FN1CCCC1C#N SSKBPPNEPSALEP-UHFFFAOYSA-N 0.000 description 1
- LMJDWRWZTXQWTI-UHFFFAOYSA-N 2,3,3a,4,5,6-hexahydro-1h-indole Chemical compound C1CCC=C2NCCC21 LMJDWRWZTXQWTI-UHFFFAOYSA-N 0.000 description 1
- WLXYHLHNIRJAIG-UHFFFAOYSA-N 2h-benzo[e]isoindole Chemical compound C1=CC=C2C3=CNC=C3C=CC2=C1 WLXYHLHNIRJAIG-UHFFFAOYSA-N 0.000 description 1
- QMYGFTJCQFEDST-UHFFFAOYSA-N 3-methoxybutyl acetate Chemical group COC(C)CCOC(C)=O QMYGFTJCQFEDST-UHFFFAOYSA-N 0.000 description 1
- BWCDLEQTELFBAW-UHFFFAOYSA-N 3h-dioxazole Chemical compound N1OOC=C1 BWCDLEQTELFBAW-UHFFFAOYSA-N 0.000 description 1
- GSODHWYZNHBOHR-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-diazepine Chemical group C1CCC=NNC1 GSODHWYZNHBOHR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- LDUXMMSHEQAYMN-UHFFFAOYSA-N Cl[N+]1=CC=CC=C1 Chemical compound Cl[N+]1=CC=CC=C1 LDUXMMSHEQAYMN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000219112 Cucumis Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- DRAJWRKLRBNJRQ-UHFFFAOYSA-N Hydroxycarbamic acid Chemical compound ONC(O)=O DRAJWRKLRBNJRQ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001174911 Iasis Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- LKVBOHLXNLJOPB-UHFFFAOYSA-N S1C=NC=C1.C1=CC=C2C=CC=3C=CC=C4C5=C(C1=C2C43)C=CC=C5 Chemical compound S1C=NC=C1.C1=CC=C2C=CC=3C=CC=C4C5=C(C1=C2C43)C=CC=C5 LKVBOHLXNLJOPB-UHFFFAOYSA-N 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- DWYNIAJTSDVSMS-UHFFFAOYSA-N [Ru].[Bi] Chemical compound [Ru].[Bi] DWYNIAJTSDVSMS-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 150000007960 acetonitrile Chemical class 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UODHKHSBDHNZBK-UHFFFAOYSA-N benzene 1,2-thiazole Chemical compound S1N=CC=C1.C1=CC=CC=C1 UODHKHSBDHNZBK-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000072 bismuth hydride Inorganic materials 0.000 description 1
- BPBOBPIKWGUSQG-UHFFFAOYSA-N bismuthane Chemical compound [BiH3] BPBOBPIKWGUSQG-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000008710 crystal-8 Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UKPBEPCQTDRZSE-UHFFFAOYSA-N cyclizine hydrochloride Chemical compound Cl.C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UKPBEPCQTDRZSE-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000004032 superbase Substances 0.000 description 1
- 150000007525 superbases Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
Description
1250978 五、發明說明(1) 曼J月所屬之拮術領域 本發明係關於具有二肽基肽酶!V酵素 、 (I )所示新穎化合物,及其塩、溶合物和拔 > 彳之通式 式(I )化合物之治療用途,含通式(〗);;構物,以及通 物,及通式("、(…、(”^"^物之製藥組成 中間物。 、⑽)和(IX )之新穎 急前技1
酵素二肽基肽酶IV (DPP- IV )盘淋ρ έ 26相同,是一種分子量ll〇k達爾ί員之多月U表面醣蛋白CD 動物的組織和器官内。此酵素特別可於=,形成於哺乳 質、肺,以及前列腺和小腸之某此組键2肝、胰島、腎皮 活性又可在體液(例如血漿、血清·、、尿重大的DPP-IV DPP- IV是絲胺酸蛋白酶型酵素,具 =。 從肽類之N末端(其中預末端胺基酸主^ β ^的特性,可 丙胺酸),裂解二肽類。 疋膊胺酸,其次為 DPP - IV酵素是體内升血檐激 和肽-2(GLP-2)分解之主因。酵辛、^ ^、肚一KGLP- 1) 島素生產,因此對葡萄糖體内環境恨—強烈刺激胰臟之胰 果,所以D P P - IV抑制劑適於治 ^ 疋有直接而有利的效 尿病(NIDDM),以及與DPP-iv酵’去^防非胰島素依賴性糖 但不限於糖尿病、肥胖症、高^攸關的疾病,包含 ' por iasis、腸病、便秘、自體 皮贗病或黏膜症 、補體居間失調,例如血管球性$,失,二例如腦脊聽炎 織損壞、身心躁鬱和神經不堂产月1、脂質營養不良和組 τ症,諸如焦慮、憂鬱、失眠
1250978 五、發明說明(2) 、早發性痴呆、癲癇、痙攣、慢性痛、ΗIV感染、過敏症 、發炎、關節炎、移植排斥、高血壓、充血性心臟病、腫 瘤、壓力引起的流產。 發明内容 本發明之目的,在於製造新而有效,穩定而安全之 DPP - IV抑制劑。 本發明人等發現通式(I )之化合物,其中R1代表含氮 芳族部份,含有一或二芳族環,宜為吡啶、吡嗒啡、嘧啶 、吡畊、咪唑 '吡唑、噻唑、異噻唑、噚唑、異_唑、噚 二唑、喹啉、異喹啉、唓啉、呔哄、喹唑啉、喹Df啉、苯 并咪唑、吲唑、苯并噻唑、苯并異噻唑、苯并噚唑、苯并 _ 異噚唑、四唑或三畊環;可分別單獨由下列基之一或二加 以單或二取代:cv4烧基、氧基、鹵素原子、三鹵甲 基、甲硫基、硝基、氰基、胺基或苯基;或 一嚷吩基、咲喃基’或卞基;或 一對甲苯續醯基;或 一式1^-(]〇之酿基,其中813指€卜4烧基、苯基;以匸1-4 烷基和/或烷氧基、硝基或鹵素原子之一或以上取代之 苯基、吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或 苯乙基;六氫吡啶-1 -基、4-甲基六氫吡哄-1 -基,或吡咯 啶- 1 -基; B代表以下式(1)或(2)或(3)或(4)或(5)或(6)或(7)之 ® 基; R2代表氫原子或氟原子;
第10頁 1250978 五、發明說明(3) R3代表氟原子一 及此等化合物之塩、異構物和溶合物,具有重大優點,其 活性、作用期限、穩定性和毒性,均較先前技藝為優。 按照已接受的術語,在氟化吡咯啶基2位之碳原子構 型宜為S,而在4位的碳原子則為S或R。
本發明之一具體例包含通式(I )化合物,其中R1指含 氮芳族部份含有一或二芳族環,宜為吡啶、吡嗒畊、嘧啶 、口比啡、咪唑、吼唑、噻唑、異噻唑、—唑、異噚唑、噚 二唑、喹啉、異喹啉、唓啉、呔哄、喹唑啉、喹噚啉、苯 并咪唑、吲唑、苯并噻唑、苯并異噻唑、苯并噚唑或苯并 異曙tr坐環;在指定情況下,彼此單獨由下列基之一或二加 以單或二取代:Ch烷基、Ch烷氧基、鹵素原子、三鹵甲 基、甲硫基、硝基、氰基;或 一嚷吩基或咲喃基;或 一對甲苯磺醯基;或 一式Rla-C0之酸基,其中Rla指Ch烧基、苯基;以一 或以上烷基和/或烷氧基、硝基或齒素原子取代之苯基、 吡啶基或苯基乙烯基;以烷二氧基取代之苯乙烯基或苯乙 基;六氫喵咬-1 -基、4 -甲基六氫D比哄-1 -基、Π比哈咬-1 -基;
B代表以下式(1)或(2)或(3)或(4)或(5)或(6)或(7)之 基; R2代表氫原子或氟原子; R3代表氟原子一
第11頁 1250978 五、發明說明(4) 及其塩、異構物、互變溶合物和水合物。
本發明次一具體例包含通式(I )之化合物,其中R1指 含氮芳族部份含有一或二芳族環,宜為吡啶、吡嗒畊、嘧 啶、吼哄、咪唑、吼唑、噻唑、異噻唑、噚唑、異噚唑、 Pf二峻、喹啉、異喹啉、唓啉、吹哄、喹唑啉、喹噚琳、 苯并咪唑、吲唑、苯并噻唑、苯并異噻唾、苯并噚唑或苯 并異噚唑環;在指定情況下,彼此單獨以下列基之一或二 加以單或二取代:Cw烷基、Ch烷氧基、i素原子、三鹵 甲基、甲硫基、硝基、氰基;或 一嗦吩基或咲喃基;或 一對甲苯石黃醯基;或 —式Rla-C0之醯基,其中Rla指Ch烷基、苯基;以一 或以上烷基和/或烷氧基、硝基或鹵素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 ;六氫〇比咬- 1 -基、4 -甲基六氫口比哄- 1 -基、口比洛淀- 1 -基; B代表式(1 )之基; R2代表氫原子或氟原子; R3代表氣原子一 及其塩、異構物、互變溶合物及水合物。
本發明另一具體例包含通式(I )之化合物,其中R1指 含氮芳族部份含有一或二芳族環,宜為耻咬、D比塔卩井、, 啶、吼畊、咪唑、哦唑、噻唑、異噻唑、噚唑、異噚唑、 Pf二唑、喹啉、異喹啉、咩啉、呔哄、喹唑啉、喹噚啉、 苯并咪嗤、吲嗤、苯并噻嗤、苯并異噻嗤、苯并噚唑或苯
第12頁 1250978 五、發明說明(5) 并異曙唑環;在指定情況下,彼此單獨以下列基之一或二 加以單或二取代:Ch烷基、Ch烷氧基、鹵素原子、三鹵 甲基、甲硫基、确基、氰基;或 一嚷吩基或咲喃基;或 一對甲苯磺醯基;或 一式Rla-C0之醯基,其中Rla指Ch烷基、苯基;以一 或以上烷基和/或烷氧基、硝基或鹵素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 ;六氫哦啶-1 -基、4-曱基六氫吡畊-1 -基、π比咯啶-1 -基; B代表式(2 )之基;
R2代表氫原子或氟原子; R3代表氟原子一 及其塩、異構物、互變溶合物和水合物。
本發明又一具體例包含通式(I )之化合物,其中Ri指 含氛芳族部份含有一或二芳族環,宜為批咬、吼塔哄、嘴 啶、批畊、咪唑、吡唑、噻唑、異噻唑、噚唑、異噚唑、 噚二唑、喹啉、異喹啉、唓啉、呔畊、喹唑啉、喹Pf啉、 苯并咪唑、吲唑、苯并噻唑、苯并異噻唑、苯并噚唾或苯 并異噚唑環;在指定情況下,彼此單獨以下列基之一或二 加以單或二取代:Ch烷基、Ch烷氧基、鹵素原子、三鹵 曱基、曱硫基、确基、氰基;或 一嚷吩基或咲喃基;或 一對曱苯磺醯基;或 —式Rla-C0之醯基,其中Rla指Ch烧基、苯基;以一
第13頁 1250978 五、發明說明(6) 或以上烷基和/或烷氧基、硝基或函素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 :六氫哦啶-1 -基、4 -甲基六氫D比畊-1 -基、吼咯啶-1 -基; B代表式(3 )之基; R2代表氫原子或氟原子; R3代表氟1原子一 及其塩、異構物、互變溶合物和水合物。 本發明又一具體例包含通式(I )之化合物,其中R1指 含氮芳族部份含有一或二芳族環,宜為吡啶、吡嗒哄、嘧 咬、批哄、咪17坐、哦σ坐、嗦嗤、異嗦嗤、曙吐、異曙σ坐、 嗜二嗤、喹啉、異喹琳、唓啉、呔哄、喹唑啉、嗤噚啉、 苯并咪嗤、吲嗤、苯并噻唑、苯并異噻嗤、苯并噚嗤或苯 并異噚唑環;在指定情況下,彼此單獨以下列基之一或二 加以單或二取代:Ch烧基、Ch烧氧基、鹵素原子、三鹵 曱基、甲硫基、硝基、氰基;或 一嚷吩基或咲喃基;或 一對甲苯石黃醯基;或 一式Rla-C0之醯基,其中Rla指Ch烧基、苯基;以一 或以上烷基和/或烷氧基、硝基或鹵素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 ;六氫吡啶-1 -基、4 -曱基六氫吡哄-1 -基、吼咯啶-1 -基; B代表式(4)或(5)之基; R2代表氫原子或氟原子; R3代表氟原子一
第14頁 1250978 五、發明說明(7) 及其塩、異構物、互變溶合物和水合物。
本發明又一具體例包含通式(I )之化合物,其中R1指 含氮芳族部份含有一或二芳族環,宜為吡啶、吡嗒畊、嘧 啶、批畊、咪唑、吡唑、噻唑、異噻唑、噚唑、異噚唑、 噚二唑、喹啉、異喹啉、唓啉、呔哄、喹唑啉、喹噚啉、 苯并咪唑、π引唑、苯并噻唑、苯并異噻唑、苯并噚唑或苯 并異噚唑環;在指定情況下,彼此單獨以下列基之一或二 加以單或二取代:Ch烷基、Ch烷氧基、鹵素原子、三鹵 甲基、甲硫基、硝基、氰基;或 一嚷吩基或咲喃基;或 一對甲苯石黃醯基;或 —式Rla - C0之酿基,其中Rla指Ch烧基、苯基;以一 或以上烷基和/或烷氧基、硝基或鹵素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 ;六氫口比咬- 1 -基、4 -甲基六氫口比畊- 1 -基、吼口各°定- 1 -基; B代表式(6)或(7)之基; R2代表氫原子或氟原子; R3代表氟原子一 及其塩、異構物、互變溶合物和水合物。
通式(I )較佳化合物係其中R1,B,R2, R3如表1至3所列, 包含其任意組合物。例如(2S)-4,4 -二氟-1-(2-{[8-(2-口密 σ定基)-8 -氮双環[3,2,1]辛-3-基]挂胺基}乙基)-2-D比咯 σ定膳;(2S,4S)-4 -氟-1-(2-{[8-(2 - D比哄基)-8-氮双環[3, 2,1]-辛-3-基]挂胺基丨乙酸基)-2 - D比咯σ定臆;(2S)-4,4-
第15頁 1250978 五、發明說明(8) 二氟-1-(2-{[ 1-(2-吡畊基)六氟吡啶-4-基]胺基丨乙醯基) - 2-吼咯啶腈;(2S)-4,4-二氟-1 -(5-氰基吡啶-2-基)六氫吡啶-4-基]胺基}乙醯基)-2-吡咯啶腈;(2S)-4, 4 _二氟-1_(2-{[1-(6 -氯π比哄-3_基)六氫卩比11 定-4 -基]胺基} 乙醯基)-2-吡咯啶腈;(2S)-4,4-二氟_l-(2-{1-(6-氰毗 口井-3-基)六氫唯咬-4 -基]胺基}乙醯基)-2 -哦嘻。定膳; 「含氮芳族部份含有一或二芳族環」一辭包含本專利 申請案優先權日時已知之所有此類環系。 「鹵素原子」指氟、氣、溴、碘原子。「Ch烷基」和 「C η烷氧基」指含1 - 4個碳原子的直鏈或支鏈脂族烴基。
本發明通式(I )化合物,可由通式(Π ) —級胺(其中R1 和Β意義同上),以通式(瓜)之氯乙醯基衍生物(其中R2和R3 意義同上)加以烷化製成,如有需要,再將所得化合物轉 變為其塩或溶合物之一(反應式1)。
(ΠΙ) Fig. 3 R1-Β-叫 + (Η)
Fig. 2
第16頁 1250978 五、發明說明(9)
反應式1 在烷化過程中,過量施加通式(m )之氯乙醯基衍生物 ,所得氯化氫利用各種酸結合劑加以結合,最好是鹼,例 如三乙胺、碳酸鉀、1,8 -二氮双環[5, 4, 0]十一碳-7-烯 (DBU),或2-三級丁基亞胺基-2-二乙胺基-1,3 -二甲基全 氫-1,3, 2-二氮磷結合於樹脂(PBEMP),稱為超鹼。反應以 在2 5和7 0 °C間之溫度進行為佳。 通式(Π )之一級胺是以二階段合成製造(反應式2)。
X R1 -
HB
Y (X) Fig· 10 R1-
B
Y (V) Fig. 5 (IV) Fig. 4
第17頁 1250978 五 、發明說明(10) R1 -
B % 反應式2 在第一階段裡, 氫原子、乙醯基或=^ x、(汉)之原料璟刑一 化物(其中β 1同上,^二及丁氧羰基)宜用;^、、及胺(其中Y為 ,若# θ + Χ代表鹵素原通式(Χ)的芳基鹵 方。化反應是在極性、ϋ子)加以芳化。視RI的意 間,最好在醇(乙醇、正^ =質子性溶劑内,於25和 J爐内,不用溶劑’使用 L =醇)内’或在微 進仃。 別 例如過量胺或DBU内 已知f,料有使4用乙通,胺(Γ之游離胺或受保護二級胺(文獻上 《iW 基六氫吡啶(β=式(1),Y= coch3)(見 气Μ予,要》1996年64,6664);4~三級丁氧羰基胺基六 風吼咬(Β=式(1),y=COOC(Ch3)3)(見 J· Med· ChenKl999 ’42’ 2706),3_(S)-三級丁氧幾基胺基六氫卩比α定(b =式 (2)和3-(S)-三級丁氧羰基胺基吡咯啶=式(3))(Synth· Comm· 1 9 98,28,3919),在後二情況下,Y=COOC(CH3)3; 三級丁基-8-氮双環[3, 2, 1]辛-3-基技胺基曱酸酯(B =式 (4)),二級丁基-8—氣双環[3,2,1]辛-3-基橋胺基甲酸酉旨 第18頁 1250978 、發明說明--—--- -〇一备气7(^?)(厂 ^1^€1111991,34,6561),三級丁基 一;又環[3, 3, 1]壬-3-基挂胺基甲酸酯(^=式(6))·以 了基—9一氮双環[3,3,1]壬一3 一基橋胺基甲酸酷(’β= )' J· Med· Chem,1 9 93,36,3 72 0 )(y = c〇OC(CH3)3 在第二階段中,利用酸水解從通式(v )之芳化胺(其 中R和B同上)除去保護基γ。反應是在塩酸水溶液或氣化氫 乙醇溶液内,於25和78 t:間之溫度進行,產生通式(n )之 脂族或環型一級胺(其中Ri和B同上)。 一 若R1代表式Rla—CO之醯基,通式(JV)之化合物(其中γ為 二級丁氧羰基)與通式Rla-COZ之酸衍生物(其中2:為裂解基 ’以氯原子為佳),宜在0°C左右之溫度,使用有機鹼,最 好是三乙胺,作為酸結合劑進行反應。從通式(V )之化合 物’在酸性條件下,最好使用三氟乙酸在二氯甲烷溶液内 ’於0-30°C把保護基Y裂解,而得通式(jj)之胺類,其中ri 為式Rla-C0之基。 通式(Π )之卜(2-氣乙醯基)〜2-π比嘻咬甲腈(其中R2和 R3同上),分四階段合成(反應式3)。
第19頁 1250978
第20頁 1250978 五、發明說明(13) 生物為佳(其中R2和R3同上),其氮以三級丁氧羰基保護。 此等化合物可利用文獻所寫方法製造(Tetrahedron Lett. 1 9 9 8,3 9,1 1 6 9 )。在第一階段,由特戊醯氯和氯曱酸乙 _製成混合酑,再形成通式(ΥΠ )之胺基甲醯基衍生物(其 中R2和R3同上)。反應以在鹵化溶劑(CHCl3, CH2C12)内,於 〇 - 25°C進行為佳。 在第二階段,三級丁氧羰基在氣化氫乙醇溶液内裂解 ’在0-25 °C發生水解,得通式(观)之甲醯胺塩酸塩(其中R2 和R3同上)。 如此所得通式(VD )之氟化D比略咬甲酿胺,在第三階段 以氣乙醯氣最好於鹵化溶劑(CHCI3, CHJl2)内,在Ot醯化 鲁 。因此,形成通式(K)之氯乙醯基胺基曱醯基衍生物(其 中R2和R3同上)。 在第四階段裡’將通式(IX )之氣乙隨基胺基甲醯基衍 生物脫水’產生通式(Π)之氣乙醯氰基衍生物(其中R2和R3 同上)。脫水宜用磷醯氯,在二氯甲烷内,於反應混合物 沸點進行。 生理研究 通式(I )化合物之D D P - I V酵素抑制活性,以下列方法 測定。 檢驗應用條件 DDP_ I V來源:由CaCo/Tc-7細胞之可溶性粗萃取物 _ 内容:0.8-l//g /檢驗 基材 :H-Gly-Pro-AMC(Bachem)
第21頁 1250978 五、發明說明(14) 反應 停止溶液 反應混合物 樣本在3 7 °C預孵育1小時 在3 7 C反應時間3 〇分鐘 1M乙酸納气衝器(pH = 4· 2) 1 〇 V 1酵素溶液 1 〇 // 1測試化合物或檢驗緩衝液 55// 1檢驗緩衝液 2 5 // 1基材 測量 3 0 0 /z 1停止溶液 " :利用Tecan板閱讀機之攝像螢光測定 (刺激:36 0nm 發射:46 5nm)
酵素和H — Gly一Pro-AMC基材之反應,利用AMC (7'胺基一 甲基薰草素)在100 mM Tris-HCl,pH二7·5(檢 驗缓衝液)内,於37 °C釋出,加以記錄。AMC的標準曲線筆 直到3 1 · 2 5 β Μ濃度,此即使用所形成AMC之相對螢光單位 (RFU)的原因。使用36〇nm刺激和465nm發射濾波器(30 # s 整合時間,Gain 25,閃光50次),利用Tecan Spectrof luor PI us板閱讀機檢測。在如此條件下,酵素 反應係直線至少3 0分鐘,而酵素依賴性係直線達2 · 5 // g蛋 白(達 700 RFU)。對 Η-Gly-Pro - AMC 使用 萃取蛋,
Km為5 0 // Μ。基材濃度高於5 〇 〇 # Μ造成螢光檢測問題(内部
濾波器效應),可藉樣本稀釋解決。 檢驗設計來盡量有效檢測活性抑制器,在3 7 C使用預 孵育時間60分鐘。檢驗進行是將(K8-l//g蛋白萃取物之1〇 以1酵素溶液(使用檢驗緩衝液:100mM Tris_HCl,pH-
第22頁 1250978 五、發明說明(15) 1仏十铉榭液(#昭 ,加在含測試化合物1 0 // 1容量和5 5 β 1檢疋級衝欣1訂… 使用6 5 /i 1檢驗緩衝液)之井内。經預孵育期後’添加2 5 // 1 1 mM H-Gly-Pro-AMC基材溶液(最後濃度2 5 0 #幻’開 始反應。最後測試容量為1 0 0 # 1,測試溶液含1 % DMS〇, 來自測試化合物溶液。在3 7 °C反應時間3 0分鐘,添加3 0 0 //1 1M乙酸鈉緩衝液(pH = 4.2)以停止反應。所形成AMC的 螢光(RFU)使用360nm刺激和465nm發射濾波器,在Tecan Spectrofluor Plus 板閱讀機(30/zs 整合時間,Gain 25, 閃光5 0次)内檢測。使用對照之RFU和空白之RFU,計算 抑 制% 小 =月通式("化合物的酵素抑制效果性 於 1 0 OnM。 通式(I )之化合物及其塩、溶合物 已知方法配製成口服或腸外投服的製藥纟ϋ異構物’可利用 多種製藥上接受之佐劑混合,並可以^ f 適當之單一劑型包括口服型,諸如 明膠膠囊、粉劑、粒劑和口服液或懸浮、Γ劑、硬質或軟質 氣管、眼球、鼻腔内劑型,利用吸入,液,舌下、頰邊、 下、肌肉或靜脈内劑型、直腸劑型和植局部、經表皮、皮 途,本發明化合物可用霜劑、凝膠劑、t型。對於局部用 舉例而言,本發明化合物之單 膏劑或洗劑 如下成份·· 通式(I )化合物 甘露糖醇 5〇· 0毫克 2 2 3 · 7 5 臺夯. 物,與一種或 劑型投服。 ^ m sx, m ° 型呈錠劑型,包括
第23頁 1250978 五、發明說明(17) 。熔點 113-115°C,UMRUOO MHz,CDC13) : 5 1· 34(s, 9H),1.49(t,2H),1·66 - 1·97(ιη,6Η),3.89(br,lH), 4.61(d,2H), 6.60(t+br,l+lH), 8.34(d,2H)。 (b) 8_(2-嘧啶基)-8-氮双環「3, 2, 11辛-3-基挂胺,通 式(Π ),其中R1和B同步驟(la)。 取13克8-(2_嘧啶基)-8 -氮双環[3,2,1]辛-3-基挂胺 基甲酸三級丁酯(43毫莫耳),溶於120毫升三氟乙酸和120 毫升三氯甲烷之混合物内。溶液經攪拌3 0分鐘,加以蒸發 。重複此法三次,最後有機溶液用1 0 0毫升羰酸鈉飽和水 溶液萃取,分層,把水層用4 x50毫升二氯甲烷洗淨。合 併有機層在Na2S04上乾燥,蒸發而得白色粉末,用正己烷 碾製。產量:6. 7 克(77% ),熔點 5 6- 59 °C。NMR(400 MHz, DMSO-d6) : 5 1. 29(t, 2H), 1. 64-1. 98 ( ra, 6 Η ), 3.19 (m,lH),4.58(dd,2H),6.57(t,lH),8.33(d,2H)。 (c) (2S)-2-(胺羰基)-4,4 -二氟-卜吡咯啶羧酸三級丁 酯,通式(VD ),其中R2和R3指氟原子。 取5.7克(22.7毫莫耳)(2S)-2-(胺羰基)-4,4-二氟-2-吼略咬羧酸三級丁酯(Tetraher on Lett· 1998,39,1169) ,溶入57毫升二氯甲烷内,於此溶液添加3·8毫升(27.2毫 莫耳)三乙胺。於所得混合物,滴加在_ 1 5 °C的3毫升(2 5毫 莫耳)特戊醯氣,混合物在此溫度攪拌1小時,再滴加7毫 升2 5 %氨水溶液,混合物攪拌1小時。反應混合物用水、 IN NaOH溶液,再用水洗淨,在硫酸鈉上乾燥,並蒸發。 添加二乙醚,晶析出3 · 9 4克(6 9 % )之上述生成物。熔點
第25頁 1250978 五、發明說明(18) 1 36 - 1 38 °C。1 -NMRC 40 0 MHz,CDC13) : 5 1· 48(s,9H) ; 2· 3 -2.9(m,3-CH2),3.69(br*,次要)+ 3·86(ιη,主要)(5-CH2), 4.53(br,2 -CH),6.0(br,主要)+6.81(br,次要)(NH2)。 (d ) (ISJzA, 4 -二氟-2 -吡咯啶甲醯胺塩酸塩,通式 (VDI ),其中R2和R3指氟原子。 取3· 93克(15·7毫莫耳)(2S)-2-(胺羰基)-4,4-二氟-1 -耻咯啶羧酸三級丁酯,溶於75毫升25%氣化氫乙醇溶液 内’在室溫攪拌4小時。於所得懸浮液,加1 5 0毫升二乙醚 ,濾除所得白色結晶性材料,得2 · 5 5克(8 7 % )上述生成物
。熔點·· 232-233 °C。NMR(40 0 MHz,DMSO-d6) : (5 2· 43 - 2.51(m,次要)和 2·81 - 3·05(ιη,主要)(3-CH2), 3. 71(t,2H, 5-CH2),4· 46(t,1H,2-CH),7· 81(s,1H) + 8· 12(s,1H)(NH2 ),10· 12(br,2H,NH2+) 〇 (e ) ( 2.g_i-1 - ( 2二^乙醯基)-4,4 - 2 -吡咯啶甲醯胺,通 式(K ),其中R2和R3指氟原子。 取2· 54克(13· 6毫莫耳)(2S)-4,4-二氟-2-吡咯啶甲醯
胺塩酸塩,懸浮於25毫升二氯甲烷内,於懸浮液加4. 1毫 升(2 9 · 3宅莫耳)二乙胺。於所得混合物,滴加—1 〇它以下 在20毫升二氯甲烷内的1·2毫升(15毫莫耳)氣乙醯氯。攪 拌1小時後’把懸浮液傾注入4 5 0毫升乙酸乙酯内,滤除析 出的三乙胺塩酸塩,將濾液蒸發,利用層析法精製,使用 氣仿-甲醇4 : 1混合物洗提液。得3 · 0克(9 7 % )上述生成物 ,呈無色油狀。 β-NMR(400 MHz,DMS〇-d6): 6 2·34-2·52(ιη,1Η) +
第26頁 1250978 五、發明說明(21) 2H), 6.59(d,lH), 7.77(d,lH), 8.07(dd,lH), 8.17(d, 1H) 〇 (b)8-(2-吡哄基)_8 -氮双環[3, 2, 1 1辛-3-基挂胺,通 式(Π ),其中R1和B同步驟(2a)。 取3·85毫克8-(2-σ密咬基)-8 -氮双環[3,2,1]辛-3-基 技胺基甲酸三級丁酯(1.26毫莫耳),溶入20毫升12%塩酸 乙醇溶液内,溶液攪拌7小時。於形成之懸浮液加2 0毫升 水’用氫氧化卸水溶液調pH至11。分層,把有機相乾燥、 蒸發,利用管柱層析法精製,使用乙酸乙酯-甲醇-2 5 %氨 水溶液(17:3:1)為洗提液,得淡黃色油。產量167毫克(65
1H-NMR( 400 MHz, DMS〇-d6): 5 1. 29(t, 2Η), 1.62- 1.83(m,4H), 1.84~2.00(m,2H), 3.12(sp,lH), 4.57(dd, 2H), 7.74(d,lH), 8.05(dd,lH), 8.15(d,lH)。 ’ (c ) i2S,4S)-2(胺羰基)-4 -氟-1-D比略咬雜酸三級丁醋 ,通式(W )中R2指氫原子,R3指氟原子。 取1· 63克(7毫莫耳)(2S,4S)-l-(三級丁氧羰基)-4 - I -2-口比略唆緩酸(Tetraheron Lett· 1988,39,1169),溶
入25¾升二氯甲烧内’加ΐ·2毫升(8·4毫莫耳)三乙胺,於 混合物在-15 °C滴加0· 86毫升(7毫莫耳)特戊醯氣,攪拌/ 小時’加2毫升2 5 %氫氧化銨水溶液,攪拌1小時後,反應 混合物用水、1 N氫氧化納溶液,再用水洗,在硫酸納上乾 燥,蒸發。由二乙醚晶析〇 · 8 8克(5 4 % )標的化合物。熔點 1 73- 1 75 〇C ° #
第29頁 1250978 五、發明說明(22) 1H-NMR( 400 MHz, DMS0-d6): (5 1. 3 8 ( s, 9H), 2.07- 2.25(m,2H,3-CH2),3.49-3.67(m,2H,5-CH2),4.13(d,lH, 2-CH),5· 07 和 5. 35(br,1Η· 4-H),6. 91 + 7· 17(br,2H,NH2 )° (d ) _ 4 S ) - 4 -氟-2 -毗咯啶甲醯胺塩酸塩,通式(Μ ) 中R2指氫原子,R3指氟原子。 取4克(17· 2笔莫耳)(2S,4S)-2-(胺戴基)-4-氟-1-吼 咯啶羧酸三級丁酯,溶於75毫升的25%氣化氫乙醇溶液内 ,在室溫攪拌4小時,濾除所得白色結晶性物質,用乙醚 洗,並乾燥。因此,得2 · 5 6克(88 % )上述生成物。熔點 2 5 0 - 2 5 1 〇C。 1H-NMR(400 MHz, DMSO-d6): 5 2 . 3 1 (t, 1 Η), 2.49-2.65(m,lH), 3.46(ra,lH), 4.30(dd,lH), 5.37(d,lH), 7.71(s,lH:^8.09(s,lH)(NH2),9.7(br,2H,NH2+)。 (e ) (2S,4S) -1-(2-亂乙酿基)-4 -氣_2-卩比洛淀甲酿胺 ,通式(IX )中R2指氫原子,R3指氟原子。 取2· 54克(15亳莫耳)(2S,4S)-4_敗-2 - Π比p各σ定甲酿胺 塩酸塩,懸浮於60毫升二氯甲烷内,添加4. 6毫升(33毫升 )三乙胺。於所得混合物,於~ 1 〇 °C以下滴加溶於1 5毫升二 氯甲烷内之1 · 2 7毫升(1 6毫莫耳)氣乙醯氣。反應混合物攪 拌1小時,懸浮液傾注入5 0 0毫升乙酸乙酯内,濾除析出之 二乙胺塩酸塩’將滤液濃縮,以層析法精製,使用氯仿-曱醇4 : 1混合物。因此,得3 · 0克(9 7 % )標題化合。為無色 油,靜止中結晶。熔點為9 5 - 9 6 °C。
第30頁 1250978 五、發明說明(23) 1H-NMR(400 MHz, DMS〇-d6): 5 2 . 2 2 - 2 . 5 0 (m, 2 Η, 3-CH2),3·57 - 4.04(m,2H,5 -CH2),4.36(qv,2H,CH2C1),5·22 U,0· 5H)和 5· 39(d,0· 5H)(4-CH),7· 03(s,0· 74H)和 7· 22 (s,1Η)和 7· 56(s,0· 26Η)(ΝΗ2) ° (f)(2S,4S)-l -(2-氣乙醯基)-4-氟_2_吡咯啶甲腈, 通式(ΠΙ )中R2指氫原子,R3指氟原子。 取1. 73克(46毫莫耳)(2S,4S)-;1 -(2-氣乙醯基)-4-氟-2 -吡咯啶甲醯胺,溶入2 0毫升無水乙腈和3 0毫升無水二氣 甲烧之混合物内,加3 2毫升(2 5毫莫耳)填醯氣。混合物回 流2 4小時。把溶液傾注入另一燒瓶内’加5 0克碳酸鉀,混 合物攪拌1小時,濾除固體塩’滤液經蒸發後’得淡黃油 ,以層析法精製,使用氣仿和甲醇9 : 1混合物。上述純生 成物為0 · 6克(4 3 % )白色結晶性固體。熔點1 3 4 一 1 3 6 C。
1H-NMR(400 MHz, CDC13): 5 2. 23-2. 62 (m, 2H, 3-CH2), 3. 59- 4.06 (m,2H,5-CH2), 4. 46 ( qv, 2H, CHC 13), 4.99(m, 1H ,2-CH), 5. 36(〇, 〇. ,R3代表氟原T ° 3毫克(1. 2毫莫耳)8_(2-吡 按實施例i(g)H _ 胺基,與191毫克(1毫 哄基)-8-氣双環[^, 某一氟_2_吡咯啶甲腈反應 莫耳)(2S,4S)-1法(2製,使^氯仿_甲醇4:1混合物,製備 。生成物以層析法精
1250978 說明(24) " 其二塩酸塩。因此’得1 2 5毫克(2 9 % )標題化合物,呈白 色晶體狀,溶點 2(H-2 02 °C。〗H-NMR( 40 0 MHz,DMS〇-d6): δ1·76-1·80(ιη,4Η),1.94-2.〇l(m,4H),2·47 - 2·51(ιη,2Η ),3.64-3.80(m,lH),3·79-4·〇3(πι,2Η),4·15(ιη,1Η), 4.67(m,2H),5·03(ιη,1Η),5. 52(d,lH),7.86(2, 1Η), 8.15(dd,lH), 8.28(d,2H), 8,90和9.00(s,2H)。 實施例3 (2 S ) zl,二氟-1 -( 2 - {〜[丄一(2 -吡d井基)六氤吡啶- 4〜& ]胺...暴}_.-吡咯啶甲^_二塩酸塩 通式(I )中Ri為2 - P比哄基,b為式(1 )之基,R2和R3指氟 原子。 ()-4-乙|胺基六氫毗啶,通式(V )中 R1為2-吡畊基,γ為C〇CH3,B為式〇)之基。 取0.45宅升氯吡哄(5毫莫耳)和丨.6克4 —乙醯胺基六氫 口比淀(1 〇毫莫耳),溶於1 5毫升1 -戊醇内,回流加熱1 4小時 。將溶劑蒸發。殘餘以管柱層析法精製,使用乙酸乙酯一 甲醇-25%龍3水溶液(17:3:1)為洗提液,得〇.81克(76%) 上述結晶性生成物。熔點1 58- 1 60 °C。MHz, DMS〇-d6): (M.34(dq,2H),1.78(m,5H),3.03(dt,2H), 3·74-3.89(m,lH), 4.21(td,2H) , 7.77(d,lH,3,_H), 7.80(s,1H,NH),8.05(dd,lH,5,-H),8.31’(d,’lH,6,_H)。
(b ) 基)-4 -胺基六氫卩比咬,通式(n)中R1和B 見步驟(3a)。 取697毫克i-(2-啦ti井基)—4 -乙醯胺基六氫π比咬(3·2毫
1250978 五、發明說明(25) 莫耳),溶入1 5毫升2N塩酸内,溶液經回流加埶冷 卻後,混合物以20%氫氧化鈉處理,水溶液用、、4 j f二 二氯甲烷洗淨。合併有機層在Na2S04上乾烨,^ “八毛… 2 9 2么克(5 2 / )上述生成物,呈黃色晶體。熔 。丨!1 - NMR( 2 0 0 MHz,DMSO-cVCDC13): (5ΐ·〇9:"6ί 2Η)
1.78(d,2H), 2.78-3.31(m,3H), 3.54(m,iH), 7 7fi;d 1H ,3’-H),8.03(dd,lH,5’-H),8.29(d,lH,6,-H)。· , • 六。氫吡啶-4 -基]_麼—基} 啶甲腈二塩醆I,通式(工)中R1 為2-吡畊基,B指式(1)之基,R2和R3指氟原子。 取63宅克1-(2 -D比哄基)-4 -胺基六氫π比咬(〇 32毫莫耳 )、62宅克(28)-1-(2-乳乙酿基)-4,4-二氟-2〜0比洛咬^腈 (0.32亳莫耳),和285毫克聚合物結合2-三級丁基亞胺基一 2-二乙胺基-1,3-二甲基全氫-1,3, 2-二氮磷(p BE MP )(0.73 毫莫耳)’溶入2 〇毫升無水乙腈内,在5 5它攪拌8小時。樹 月曰經過;慮除去慮液利用真空濃縮,殘邊用管柱層析法精 製’使用乳仿-甲醇(9 : 1 )為洗提液,得油,以塩酸在二乙 醚内處理’得8 3毫克(6 0 % )標題化合物,為白色晶體。熔 點 1 58 - 1 60 °C。W-NMRMOO MHz,DMS〇-d6) : 5 1·54(ιη,2Η) ,2·15(πι,2Η),2·80-2·95(ιη,4Η),4·20-4·25(ιη,4Η), 4.55(d,2H), 5.20(t,lH), 7.00(d,lH), 7.87(dd,lH), 8· 50(d, 1H),9· 38(br,2H)。 實施例4 L_2_S.). —4, 4一 二氟一1一(2一{ [ ;[ 一(5-氰口比 口定一2-基)六氫 口比咬
第33頁 1250978
吡咯啶甲腈二塩酸塩,通式(!) "基,B指式⑴之基,R2和R3指氣原子 -基)- 4 -乙醯胺基六氫π比p定,通式 (v )中乂之基通式 ^ 實施例3(a)所列程序,單離上列結晶性生成物。 溶點 246 —25 1 C。1H,R(20 0 MHz,DMSO-d6) : (5 1. 19-
1.39(m,2H), 1.82(m,5H), 3〇4—318(ra,2H), 3.85(m 1H ),4.29(dd,2H), 6.94(d,lH), 7.82(dd,lH), 8.46(d,lH —基)—4—胺基六氫吡啶,通式(n) 中R1和B如步驟(4a)。 按照實。施例3 (b)所列程序,單離上列結晶性生成物。 溶點 6 5-6 8 °C。{-NMR( 20 0 MHz,CDC13-DMS0-d6) : 5 1· 16-1.38(m,2H),1·83-1·92(ιη,2Η),2·89-3·06(ιη,2Η),4·26 (dd,2H),6.54(d,lH),7.50(dd,lH),8.29(d,lH)。 氟- l-(2-{ [1-(5 -氰吡啶-2-基)六氫 哩^ - 4二基1.JL暴JLg^基)-2 -吡咯啶曱腈二塩酸塩 按照實施例3 ( c)所列程序,單離上列結晶性生成物。 熔點 1 46- 1 47 °C。W-NMRCDMSO-d6) ·· 5 1· 56(m,2H),2· 15 (d,2H),2.92(m,4H),4.20(m,4H),4.55(d,2H),5.20(t ,2H),7.01(d,lH),7.88(d,lH),8.49( dd,lH),9.38(d, 2H) 〇 按照實施例1 - 2所述程序,製造表1所列化合物,呈游 離驗或ί显。
第34頁 1250978
實施例 R1 B (式) R2 R3 熔點,組成份,實體外觀 5. (4) F F 133-141°C,二塩酸塩, 灰白晶體 6· /Nv V (4) F F 238-240 °C,二塩酸塩, 黃晶體 7. (4) F F 237_239°C,二塩酸塩, 白晶體 8, /NV !ί I (4) F F 160-162 °C,黃晶體 9. αΆ〆 (4) F F 119-121 °C,二塩酸塩, 白晶體
IlIHll 第35頁 1250978 五、發明說明(28) 10. (4) F F 221-225 °C,三塩酸塩, 白晶體 11. (4) F F 200-201 °C,二塩酸塩, 白晶體 12. ¥ 丫 V (4) F F 185-189 °C,二塩酸塩, 白晶體 13. ;CA> (4) F F 108-110 °C,白晶體 14· rN< (4) F F >340 °C,二塩酸塩, 灰白晶體 15. (4) F F 300-305 °C,二塩酸塩, 白晶體 16· (4) F F 185-186 °C,二塩酸塩, 黃晶體 17. a\,NV (4) F F 293-296 °C,二塩酸塩, 白晶體 18. N^N (4) F F 148-167 °C,二塩酸塩, 白固體 第36頁 1250978 五、發明說明(29) 19. /Nv NC^^N'^ (4) F F >350 0C,1,5 HC1, 白晶體 20· (4) F F 240-243 °C,二塩酸塩, 白晶體 21. 〔V (4) F F 102-104 °C,白晶體 22. (4) F Γ 236-241 °C,三塩酸塩, 白晶體 23. ⑷ F Γ 201-202 °C,二塩酸塩, 白晶體 24· f^V- (4) Γ F 256-259 °C,二塩酸塩, 白晶體 25. /Ν' i! 、‘)— (4) F F 119-120 °C,黃晶體 26. 6 (4) F F 114-117 °C,白固體 27· 〇 (4) F F 94-97 °C,白固體 28· NC /、、义 (2) F F 66-70 °C,白泡綿 第37頁 1250978 五、發明說明(30) 29. 八/ NC,、々 (3) F F 216-218 °C,二塩酸塩, 白晶體 30. 八/ (5) F F 182-185 °C,白固體 31· 八/ V (5) F F 241-243 °C,三塩酸塩, 黃晶體 32. 八/ (6) Γ Γ 276-278 °C,二塩酸塩, 黃晶體 33. (6) F F 240-243 °C,二塩酸塩, 頁日日體 34· rrv (6) F F 82-85 °C,塩酸塩, 灰白晶體 35. (7) F Γ 141-144 °C,白晶體 36· Ν〇Α^ (7) F F 281-284 °C,二塩酸塩, 黃晶體 37. \於,〇 (7) F F 271-272 °C,二塩酸塩, 灰白晶體 第38頁 1250978 五、發明說明(31) 按照實施例3-4所述程序,製造表2所列化合物,呈游 離驗或塩。 „2 〇3
(I) 實施例 R1 Β (式) R2 R3 熔點,組成份,實體外觀 38. (1) F F 219-228 °C,二塩酸塩, 白晶體 39. ,NV !1 ! (1) F F 198-200 °C,二塩酸塩, 白晶體 40. Μ ! (1) Γ F 224-229 °C,三塩酸塩, 灰白晶體 41· Η /ί '、Ν〆 (1) H F 157-158 °C,淡黃晶體
第39頁 1250978 五、發明說明(32) 42. (1) F F 2,5HC1,非晶形白色固定 43. 八/ Μ (1) F F 292-295 °C,二塩酸塩, 白晶體 44· (1) F F 210-212 °C,二塩酸塩, 白晶體 45. (i) F F 284-288°C,二塩酸塩, 白晶體 46· BrA^j (i) Γ F 282-285 °C,二塩酸塩, 灰白晶體 47. .XT (1) F F 170-173 °C,二塩酸塩, 黃晶體 48· NC〜 (i) H F 122-124 °C,白晶體 49. hcW (1) F F 102-105 °C,二塩酸塩, 白晶體 50 n,nv 丨丨 : NC八夕 (1) F F 63-65 °C,白晶體 51· n,NV (1) F F >350 °C,二塩酸塩, 白晶體 iiiiii 1250978 五、發明說明(33) 52· W〆 (1) F F 168-171 °C,二塩酸塩, 白晶體 53. aw Μ (i) F F 173-175 °C,二塩酸塩, -t±: μ sm 頁晶體 54· α、丫 (1) F F 162-163 QC,二塩酸塩, 白晶體 55. CV^ N^N (1) F F 二塩酸塩,非晶形灰白固體 56. NC又^ (1) F F 51-53 °C,淺黃泡綿 57· (1) F F 228-230 °C,二塩酸塩, 白晶體 58· r w (1) F F 281-284 °C,二塩酸塩, 其曰鹏 頁日日體 59. 0¾ \、' N、〇2 (1) F F 116-120 °C,二塩酸塩, 黃晶體 60. (1) F F 178-185°C,與 2.5 分子 HC1 形 成塩,白晶體 61. (i) F F 二塩酸塩,非晶形灰白固體
111 第41頁 1250978 五、發明說明(34) 62. w人w (1) F F 226-235^(:,二塩酸塩, ch3 白晶體 63. (i) Γ F 278-283 °C,二塩酸塩, 灰白晶體 64· !; ; ! (i) F F 2,5HC1,非晶形黃色固體 65. m (1) F F 318-320 °C,二塩酸塩, 白晶體 66. !! ! >— (1) F F 157-160 °C,白晶體
按照實施例1 -4所述程序,製造表3所列通式(I )化合 物,呈游離鹼或塩。 表 3
X 一一 0
(I)
第42頁 1250978 五、發明說明(35) 實施例 R1 Β (式) R2 R3 熔點,組成份,實體外觀 67. (1) F F 216-228 °C,三塩酸塩, 灰白晶體 68· - N Y 1' ! (1) F F 163-167 °C,奶油色固體 69· U <v N-N (1) F F 二塩酸塩,非晶形灰白固體 70. Mc〇、7N^/ II 1 N\夕N OMe (1) F F 275-277 °C,二塩酸塩, 白色固體 71· ii Ί <Ν>-Ν—Ν (4) F F 148-152 °C,二塩酸塩, 淡黃晶體 72. Π 1 (7) F F 229-231 °C,三塩酸塩, 白晶體
按照實施例1 ( a )和2 ( a )所述程序,製造表4所列通式 (V )之中間化合物。 表 4
第43頁 1250978 五、發明說明(36) R1 / 人0〆< \ H (V) 實施例 R1 特性(熔點LC/MS或芳族質子,利用 ^-NMR [DMSO-d6] 4.1. σ 6.93 (m,1H),7·35 (m,1H),7·98 (m,1H), 8.04 (d,1H) 4.2. 141-143°C 4.3. 212-2150C 4.4. w 6.58 (d,1H), 6·65 (d,1H),7·51 (t,1H) 4.5. HjCxx 2·37 (s,3H),6·75 (1H,d),7·15 (1H,dd), 7,81 (1H,d) 4.6. 6.75 (d, 1H), 7·60 (d,1H),8.12 (s,1H) 4.7. H3C 丫 Νγ 6.65 (d,1H),7·84 (d,1H) 1··Ι1! 1250978 五、發明說明(37) 4.8. N^V N〇^ 227-230°C 4.9. N-V 7.30 (d, 1Η), 7.51 (d, 1H) 4.10. 6·71 (d,1H),8.31 (d,1H) 4.11. C丨 161-162°C 4.12. 丨 ί 6.72 (d,1H),8.04 (d,1H) 4.13. Ν\,Ν 187-1880C 4.14. 1Υ NC Ν [MH】+ = 330 4.15. /SyV 172-174°C 4.16. CSV· 6.80 (d, 1H), 7.19 (d, 1H) 4.17. ΓΎΝ丫 6·87 (d,1H),7.20 (td,1H),7·61 (m,1H), 7,57 (m,2H),7.86 (d,1H) 4.18. ΓΎΝ丫 7.38 (td,1H),7·57 (td,1H),7·74 (dd,1H), 7,88 (dd,1H),8,45 (s,1H) 第45頁 1250978
第46頁 1250978 五、發明說明(39)
實施例 R1 B (式) 特性(熔點或芳族質子,利用W-NMR [DMSO-d6] 5丄 (2) 154-156°C 5.2. Cr (5) 134-135°C 5.3. cNr N (5) 159-161°C 5.4. (Nr N (6) 7.82 (d,1H),8·11 (d,1H),8·35 (s,1H) 5.5. (6) 6.93 (d,1H),7.91 (d,1H),8.54 (s,1H) 5·6. a:>- (6) 6,99 (t,1H),7·13 (t,1H),7·26 (d,1H), 7.36 (d,1H) 5.7. cr (7) 6.50 (t,1H),8·33 (m,2H) 5.8. (7) 6·90 (d,1H),7·80 (d,1H),8·44 (s,1H) 5.9. αν (7) 6.98 (t, 1H), 7.12 (t, 1H), 7.29 (d, 1H), 7.39 (d,1H) 5.10. (7) 176-176°C
第47頁 1250978 五、發明說明(40) 按照實施例3 (a)和4 ( a )所述程序,製造表6所列通式 (V )之中間化合物,其中Y = Ac(乙醯基),或Boc =三級丁 氧幾基。 表 6
(V) 實施例 R1 Y 特性(熔點LC/MS或芳族質子,利用 ^-NMR [DMSO-de] 6.1. σ Ac 6·60 (dd,1H),6.67 (d,1H),7·48 (td,1H), 8.17 (dd,1H) 6.2. Cr Boc 127-129°C 6.3. rV Boc 138-140°C 6.4. A Ac 2·12 (s,3H),6·74 (d,1H),7·33 (dd,1H), 7·76 (d,1H) 6.5. Ac 166_164°C 6.6. CVN^/ 丨 : Boc 6·58 (d,1H),6·65 (d,1H),7·51 (t,1H)
第48頁 1250978 五、發明說明(41) 6.1. c,iy Ac 6.65 (d, 1H),7.45 (dd,1H),8·10 (d,1H) 6.8. Ac 6.72 (d,1H),7.60 (d,1H),8·13 (s,1H) 6.9. Ac 223-226°C 6.10. H3CxX Boc 139-140°C 6.11. Ν〇^ Ac 126-128°C 6.12. 〇,aJ Boc 6.95 (d,1H), 7·22 (d,1H) 6.13. ί; 1 Μ Μ Boc 169-171°C 6.14. V Boc 144-146°C 6.15. w 丨丨 ! Boc 172-174°C 6.16. C,>r-V Ν^Ν Boc 149-152°C 6.17. iNr NC’'N’ Boc [MH】+ = 304
ΙΙΙ11» 第49頁 1250978 五、發明說明(42)
6.18. Ac 196-200°C 6.19. Ac 6.80 (d,1H),7.12 (d,1H) 6.20. <x no2 Ac 234-236°C 6.21. ca Ac 163-166°C 6.22. xxy Boc 7.59 (m,3H),8.10 (m,1H),8.29 (d,1H) 6.23. Oc^r ch3 Boc 129-133°C 6.24. 06 Boc 7·49 (d,1H),7.72 (td,1H),7.85 (td,1H), 7·90 (t,1H>,7·98 (d,1H),8·13 (d,1H) 6.25. ax Boc 7·38 (td,1H),7·57 (td,1H),7·74 (dd,1H), 7·88 (dd,1H),8.45 (s,1H) 6.26. av Ac 7.01 (t,1H),7.27 (t,1H),7·42 (d,1H),7.73 (d,1H) 6.27. av Boc 165-166°C ΙΙΙΙϋΙ 第50頁 1250978 五、發明說明(43)
6·28· Boc 206-211°C 6.29. Ρ .νν^ \~1Γ Boc 7,5 (m,5H) 6.30. Me° w OMc Boc 159-160°C
按照實施例1 (b)和2 (b)所列程序,製造表7所列通式 (Π )之中間化合物。 表
(Π)
第51頁 1250978 五、發明說明(44) 實施例 R1 特性(熔點或芳族質子,利用iH-NMR [DMSOd6] 7.1. σ 6·96 (m,1H),7.34 (m,1H),8·02 (m,1H), 8.08 (d, 1H) 7.2. 123-125°C 7.3. 175-178°C 7.4. U 6·55 (d,1H),6·63 (d,1H),7·49 (t,1H) 7.5. HiCXX 2,40 (s,3H),6,82 (dd,1H,),7,20 (d,1H), 7,89 (d,1H) 7.6. 6.40 (d,1H),7.60 (d,1H),8·14 (s,1H) 7.7. xc 2.35(s,3H),6.62 (d,1H),7.81 (d,1H) 7.8. N^V n〇aJ 120-123°C 7.9 N-V 〇,aJ 7.32 (d,1H),7.58 (d,1H), 7.10. c 丨 6.68 (d,1H),8.29 (d,1H)
ϋ_Ι 第52頁 1250978 五、發明說明(45) 7.11. clvNV V 7.77 (s, 1H), 8.13 (s, 1H) 7.12. 6.69 (d, 1H), 8.02 (d, 1H) 7.13. 194-198°C 7.14· iy NC’ N 115-117°C 7.15. /SyV 2·40 (s,3H),6·40 (d,1H),7·87 (d,1H) 7.16. 〇 6·79 (d,1H),7.12 (d,1H) 7.17 ca 6·86 (d,1H),7.19 (td,1H),7.52 (m,2H), 7,69 (dd,1H),7·84 (d,1H) 7.18 ax 7·35 (m,1H),7.58 (m,1H,),7.80 (dd,1H), 8,66 (s,1H) 7.19 co· 126-127°C 7.20. av 127-129°C 7.21. oa^ O 90-93 °C _ ΒΙΕΙ 第53頁 1250978 五、發明說明(46) 7.22 〇 107-107 °C 7.23. 227-228°C as dihydrochlorid 丫 N;V Ν-Ν 按照實施例1 (b)和2 (b )所列程序,製造表8所列通式 (Π )之中間化合物。 表 8
R1-B-NH2 (II)
實施例 R1 B (式) 特性(熔點或芳族質子,利用iH-NMR [DMSO-d6] 8.1. (2) 6·49 (d,1H),7.76 (dd,1H),8.43 (d,1H) 8.2. cr (5) 85-89 °C 第54頁 1250978 五、發明說明(47) 8.3. CT N (5) 7.74 (d,1H),8·04 (d,1H),8.15 (s,1H) 8.4. 〔y N (6) 7.80 (d,1H),8.12 (d,1H),8.37 (s,1H) 8.5. A (6) 6.95 (d,1H),7·89 (d,1H),8·51 (s,1H) 8.6. αν (6) 7.00 (t,1H),7·14 (t,1H),7.26 (d,1H), 7.37 (d,1H) 8.7. cr (7) 6·50 (t,1H),8·29 (d,1H),8,31 (d,1H) 8.8. (7) 6·90 (d,1H),7·80 (d,1H),8.47 (s,1H) 8.9. (7) 6.95 (t,1H),7·14 (t,1H),7·26 (d,1H), 7.37 (d,1H) 8.10. 〇r^ (7) 3,83 (s,2H),7,21-7,40 (,m,5H)
按照實施例3 ( b)和4 (b)所列程序,製造表9所列通式 (Π )之中間化合物。
表 9
第55頁 1250978 五、發明說明(48)
實施例 R1 特性(熔點LC/MS或芳族質子,利用"Η-NMR [DMSO-d6] 9.1. σ 6·55 (dd,1H),6·79 (d,1H,),7·48 (td,1H),8·07 (dd,1H) 9.2. Cr 104-106°C 9.3. rV 234-236°C 二塩酸塩 9.4. J(Y 2·12 (s,3H),6·72 (d,1H),7·33 (dd,1H), 7.92 (d, 1H) 9.5. HaCxx 2·26 (s,3H),6·47 (m,2H),8·03 (d,1H) 9.6. ί! i 238-240°C 二塩酸塩
第56頁 1250978 五、發明說明(49) 9.7. 6·84 (d,1Η),7·52 (dd,1Η),8·05 (d,1Η) 9.8. 6·75 (d,1Η),7·60 (d,1Η),8·12 (s,1Η) 9.9. 86-89°C 9.10. H3C 丫 2·37 (s,3Η),6·72 (d,1Η),7·87 (d,1Η) 9.11. Ν〇^ 117-119°C 9.12. N-V 〇,aJ 135-139°C 9.13. χτ 6·65 (d,1Η),8,27 (d,1Η) 9.14. w 7·78 (s,1H),8·26 (s,1H) 9.15. 6·80 (d,1H),8,00 (d,1H) 9.16. αν^ Ν^Ν 296-303°C 二塩酸塩 9.17. 1Υ NC Ν [MH]+ = 204 第57頁 1250978 五、發明說明(50) 9·18· -vr 2·33 (s,3Η),6·51 (d,1Η), 7·96 (d,1Η) 9.19. Q>- U2-U4°C 9.20. ?Η3 《X νο2 167-170°C 9.21. ca 67-68°C 9.22. Fj〇y 7·60 (m,2Η),7·72 (d,1Η),8·15 (m,1Η), 8·32 (1H,d), 9.23. 〇7 ch3 260-262°C 二塩酸塩 9.24. 〇6 253-256°C 二塩酸塩 9.25. αχ 7·34 (m,1H),7·58 (m,2H),7.79 (dd,1H), 8.81 (s, 1H) 9.26· αν 7·03 (t,1H),7.26 (t,1H),7.42 (d,1H), 7.74 (d, 1H) 9.27. α:>- 274-275^(:二塩酸塩 ΙΙΗΠΙΙ 第58頁 1250978 五、發明說明(51) 9.28. 113-115°C 9.29. ? Ν-Ν 216-223°C 二塩酸塩 9.30. OMe 3.70 (s,6H)
第59頁 111·· 1250978 圖式簡單說明
第1圖表示通式(I )之化合物; 第2圖表示通式(n)之化合物; 第3圖表示通式(m)之化合物; 第4圖表示通式(IV)之化合物; 第5圖表示通式(V)之化合物; 第6圖表示通式(VI)之化合物; 第7圖表示通式(W)之化合物; 第8圖表示通式()之化合物; 第9圖表示通式(IX)之化合物; 第1 0圖表示通式(X )之化合物; 第11圖表示通式(1); 第12圖表示通式(2); 第13圖表示通式(3); 第14圖表示通式(4); 第15圖表示通式(5); 第16圖表示通式(6); 第17圖表示通式(7)。
第60頁
Claims (1)
1250978 案號9210 侃[「「丽 74f月日補桌 |公告本| {n__—s…1 修正 六、申請專利範圍 1 · 一種通式(I )所示化合物,及其塩 體、溶合物及其水合物: 異構物、互變
其中,R1指吡啶、吡嗒畊、嘧啶、吡畊、咪唑、吡唑、噻 唑、異噻唑、曙唑、異曙唑、曙二唑、喹啉、異喹啉、唓 啉、吹哄、喹唑啉、喹噚啉、苯并咪嗅、吲唾、苯并噻唾 、苯并異噻唑、苯并噚唑或苯并異噚唑、四唑、三畊環; 視情況,彼此單獨被一或二下列基單或二取代:XV4烷基、 Ci_4烷氧基、鹵素原子、三鹵甲基、甲硫基、硝基、氰基、 胺基或苯基;或 —节基;或 一式Rla-CO之醯基,其中Rla指Cw烷基、苯基;以一 或以上烷基和/或烷氧基或硝基或鹵素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 B 代表式(1)、(2)、(3)、(4)、(5)、(6)或(7)之 基;
第61頁
第62頁 1250978 案號 92104743 年 月 曰 修正 六、申請專利範圍 R2代表氫原子或氟原子; R3代表氟原子者。 2.如申請專利範圍第1項通式(I )之化合物,及其塩 、異構物、互變體、溶合物和水合物,其中
R1指吡啶、毗嗒畊、嘧啶、吡哄、咪唑、吡唑、噻 唑、異噻唑、噚唑、異噚唑、噚二唑、喹啉、異喹咐、唓 啉、呔哄、喹唑啉、喹噚啉、苯并咪唑、吲唑、苯并噻唑 、苯并異噻唑、苯并噚唑或苯并異噚唑;在指定情況下, 彼此單獨以一或二下列基單或二取代·· Ch烷基、Cw烷氧 基、鹵素原子、三邊甲基、甲硫基、硝基、氰基;或 一嗟吩基或咲喃基;或 一對曱苯磺醯基;或 一式Rla-CO之醯:基,其中Ri^§Ch烧基、苯基;以一 或以上烷基和/或烷氧基或硝基或豳素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 ;六氫口比咬-1 -基、4 -甲基六氫D比D井-1 -基、π比哈咬-1 -基; B代表申請專利範圍第1項中式(1 )、( 2 )、( 3 )、( 4 ) 、(5)、(6)或(7)之基;
R2代表氫原子或氟原子; R3代表氟原子者。 3 ·如申請專利範圍第2項通式(I )之化合物,及其塩 、異構物、互變體、溶合物和水合物,其中 R1指吡啶、吡嗒哄、嘧啶、吡畊、咪唑、吡唑、噻
第63頁 1250978 _案號92104743_年月曰 修正_ · 六、申請專利範圍 唑、異噻唑、噚唑、異Pf唑、噚二唑、喹啉、異喹啉、唓 啉、吹畊、喹唑啉、喹噚啉、苯并咪唑、吲唑、苯并噻唑 、苯并異噻唑、苯并噚唑或苯并異噚唑環;在指定情況下 ,彼此單獨以一或二下列基單或二取代:Ch烷基、Ch烷 氧基、鹵素原子、三鹵甲基、甲硫基、硝基、氰基;或 一噻吩基或呋喃基;或 一對曱苯績酿基;或 一式Rla-CO之酿基,其中UIC卜4烧基、苯基;以一 或以上烷基和/或烷氧基或硝基或鹵素原子取代之苯基、 . 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 _ ;六氫吡啶-1-基、4-甲基六氫吡畊-1-基、吼咯啶-1-基;β Β代表式(1 )之基; R2代表氫原子或氟原子; R3代表氟原子者。 4.如申請專利範圍第2項通式(I )之化合物,及其塩 、異構物、互變體、溶合物和水合物,其中 R1指吡啶、吡嗒哄、嘧啶、吡哄、咪唑、吡唑、噻 唑、異噻唑、噚唑、異噚唑、噚二唑、喹琳、異喹琳、唓 啉、呔畊、喹唑啉、喹噚啉、苯并咪唑、吲唑、苯并噻唑 、苯并異噻唑、苯并噚唑或苯并異噚唑環;在指定情況下 φ ,彼此單獨以一或二下列基單或二取代:Ch烷基、Ch烷 氧基、鹵素原子、三鹵甲基、甲硫基、硝基、氰基;或 一嚷吩基或咲喃基;或 一對甲苯績醯基;或
第64頁 1250978 _案號92104743_年月曰 修正_ 六、申請專利範圍 一式Rla-C0之醯基,其中Rla指Cw烷基、苯基;以一 或以上烷基和/或烷氧基或硝基或鹵素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 ;六氫卩比啶-1 -基、4-甲基六氫吡畊-1 -基、〇比咯啶-1 -基; B代表式(2 )之基; R2代表氫原子或氟原子; R3代表氟原子者。 5 .如申請專利範圍第2項通式(I )之化合物,及其塩 、異構物、互變體、溶合物和水合物,其中
R1指卩比°定、批塔畊、嘴咬、卩比哄、咪峻、耻嗤、噻 唑、異噻唑、噚唑、異曙唑、曙二唑、喹啉、異喹啉、咭 琳、吹哄、喹唾琳、喹曙琳、苯并味°坐、吗丨嗤、苯并嗟嗤 、苯并異噻唑、苯并曙唑或苯并異噚唑環;在指定情況下 ,彼此單獨以一或二下列基單或二取代:Ch烷基、Cp4烷 氧基、鹵素原子、三鹵甲基、甲硫基、琐基、氣基;或 一噻吩基或11夫喃基;或 一對甲苯磺酿基;或
一式Rla-CO之醯基’其中Rla指Ci_4烧基、苯基,·以一 或以上烷基和/或烷氧基或硝基或鹵素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 ;六氮卩比11 定-1-基、4_甲基六氮卩比哄-1-基、卩比哈°定-1-基; B代表式(3)之基; R2代表氫原子或氟原子; R3代表氟原子者。
第65頁 1250978 案號 92104743 年 月 曰 修正 六、申請專利範圍 6 ·如申請專利範圍第2項通式(I )之化合物,及其塩 、異構物、互變體、溶合物和水合物,其中
R1指吡啶、吡嗒畊、嘧啶、吡畊、咪唑、吡唑、噻 σ坐、異嚷σ坐、曙τι坐、異曙ti坐、曙二σ坐、嗤琳、異嗤琳、啥 啉、吹卩井、喹峻啉、喹噚琳、苯并咪唑、吲唑、苯并噻唑 、苯并異噻唑、苯并噚唑或苯并異噚唑環;在指定情況下 ,彼此單獨以一或二下列基單或二取代:C1M烷基、CW烷 氧基、_素原子、三函曱基、甲硫基、石肖基、氰基;或 一噻吩基或咲喃基;或 一對甲苯項醯基;或 一式Rla-CO之醯基,其中Rla指Ch烧基、苯基;以一 或以上烷基和/或烷氧基或硝基或鹵素原子取代之苯基、 吡啶基或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 ;六氫毗啶-1-基、4-甲基六氫吡畊-1-基、ϋ比咯啶-1-基; Β代表式(4)或(5)之基; R2代表氫原子或氟原子; R3代表氟原子者。 7 .如申請專利範圍第2項通式(I )之化合物,及其塩 、異構物、互變體、溶合物和水合物,其中
R1指吡啶、吡嗒畊、嘧啶、吡畊、咪唑、吡唑、噻 唑、異噻唑、噚唑、異噚唑、噚二唑、喹啉、異喹啉、唓 啉、吹畊、喹唑啉、喹噚啉、苯并咪唑、吲唑、苯并噻唑 、苯并異噻唑、苯并噚唑或苯并異噚唑環;在指定情況下 ,彼此單獨以一或二下列基單或二取代:Ch烷基、Cw烷
第66頁 1250978 案號 92104743 年月 日 倏正 六、申請專利範圍 氧基、鹵素原子、三鹵甲基、甲硫基、硝基、氰基;或 一噻吩基或呋喃基;或 一對曱苯磺醯基;或 —式Rla-C0之醯基,其中Rla指Ch烷基、苯基;以一 或以上烧基和/或烷氧基或硝基或鹵素原子取代之苯基、 口比咬^或苯乙烯基;以烷二氧基取代之苯乙烯基或苯乙基 •’六氫吡啶一丨―基、4-曱基六氫吡畊-卜基、吡咯啶-丨—基; β代表式(6)或(7)之基; ’ R2代表氫原子或氟原子; R3代表氟原子者。 2-嘴U ί申f專利範圍第2項通式(1 )之化合物,其中R1指 “;;:代吼表哄,基⑴氣和氛取㈣ 9. 如申性/t(1)之基,R^ R3代表氟原子者。 2 -嘧啶基、2 w =範圍第2項通式(I )之化合物,其中R1指 2-吡啶基;主基、氣和氰取代之吡嗒哄基、氰取代之 10. 如申式(2)之基,R^R3代表氟原子者。 指2-嘧啶基、^專利範圍第2項通式(I )之化合物,其中R〗 之2-吡啶基;β 哄基、氣和氰取代之吡嗒畊基、氰取代 1 1.如申許直 ^ (3)之基,R2和Κ3代表氟原子者。 指2-嘧啶基' H範圍第/項通式(I )之化合物,其中Ri 之2-吡啶基;β 基、氣和氰取代之吡嗒畊基、氰取代 者。 式(4)或(5)之基,R2和R3代表氟原子 12. 如申請專利範圍第2項通式(! )之化合物,其中R1
第67頁 125097^取1明打曰修(\)正本i '^ 索號一全3—-一一一一年月 日 修正 六、申請專利範圍 指2 -嘧啶基、2 -吡畊基、氣和氰取代之吡嗒哄基、氰取代 之2 -吡啶基;Β代表式(6)或(7)之基,R2和R3代表氟原子 者。 13. (2S)-4, 4 -二氟-1-(2-{[8-(2 -嘧啶基)-8-氮双環 [3, 2, 1 ]辛-3-基]挂胺基}乙醯基)-2 -吡咯啶甲腈。 14. (23,48)-4-氟-1-(2-{[8-(2-吡畊基)-8-氮双環 [3, 2, 1 ]辛-3-基]挂胺基}乙醯基)-2 -吡咯啶曱腈。 15. (2S)-4, 4 -二氟-1-(2-{[卜(2 -吡畊基)六氫吡啶-4 -基]胺基}乙醯基)- 2 -吡咯啶甲腈。
16· (2S)-4, 4 -二 It-1-(2-{[1-(5-氰吼咬-2 -基)六氫 吡啶-4-基]胺基}乙醯基-2 -吡咯啶甲腈。 17· (2S)-4,4 -二氟-1-(2-{[1-(6 -氯吡嗒畊-3-基)六 氫吡啶-4 -基]胺基}乙醯基)-2 -吡咯啶甲腈。 18· (2S)-4, 4-二氟-卜(2-{[:1-(6-氰吡嗒畊-3-基)六 氫吡啶-4 -基]胺基}乙醯基)-2 -吡咯啶甲腈。 1 9 . 一種對抗糖尿病製藥組成物,包括申請專利範圍 第1項通式(I )之化合物,或其塩、異構體、互變體、溶 合物、水合物者。
2 0 · —種製造申請專利範圍第1項通式(I )化合物之方 法:
第68頁 12509: 8^4¾%曰修(更)正本 案號92,】 04743 曰 修正 六、申請專利範圍 通 (其中R1,B,R2和R3同申請專利範圍第1項所述)其特徵為 式(Π)之化合物: (Π ) R1-B-NH, (式中R1和B同上),與通式(m)之化合物:
(Π) (式中R2和R3同上)縮合,消除生成的氯化氫,而所得通式 (I )之化合物或其塩,即從反應混合物單離者。 2 1 ·如申請專利範圍第1項之通式(I )化合物: R1 B-
I) 馨 其中R1,B,R2,R3同申請專利範圍第1項所述,用於製造製藥 配方,適於抑制DP P- I V酵素之活性,旨在治療和預防與 DPP-IV酵素活性有關之疾病者。 2 2 · —種通式(Π )之化合物,及其異構物和塩: R1——B——ΝΗ2 ( Π ) 其t R1和B如申請專利範圍第1項所界定,惟若B代表式(1) 所示之一基,則R1為非6-氯-3 -吡嗒畊基或5-氰基吡啶-2-
第69頁 ^4*· IU. Z i I 年月 日修(更)正本j
125097&年 六、申請專利範圍 基或1H-苯并嘧唑-2-基者。 2 3 . —種通式(ΙΠ )之化合物,及其異構物: R\ R3
0 ( Π ) 其中R2和R3如申請專利範圍第1項所界定者。 2 4 . —種通式(V )之化合物,及其異構物和塩: (V) 其中R1和B如申請專利範圍第1項所界定,惟若B代表式(1) 之一基,Y代表乙醯基,則R1非6, 7 -二甲氧基喹唑啉-1-基,或若B代表式(1)之基,Y代表三級丁氧羰基,則R1非5-氰基吡啶-2 -基,或若B代表式(3)之一基,Y代表乙醯基, 則R1非苯甲醯基者。 2 5 . —種通式(YD )之化合物,及其異構物: R\ R3
(νπ) 其中R2和R3如申請專利範圍第1項所界定者。 2 6 · —種通式()之化合物,及其異構物和塩:
第70頁 1250978 擎:月a修(更}正本 修正 六、申請專利範圍
NH, (M) 其中R2和R3如申請專利範圍第1項所界定者。 27. —種通式(IX)之化合物,及其異構物:
NH。 (IX) 其中R2和R3如申請專利範圍第1項所界定者。 2 8.如申請專利範圍第23項至27項任一項中通式(Π ) (m) ( V ) ( W ) ( Μ)和(IX )之化合物,用於製造如申請專利 範圍第1項通式(I )之化合物者。
第71頁
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0200849A HUP0200849A2 (hu) | 2002-03-06 | 2002-03-06 | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200303860A TW200303860A (en) | 2003-09-16 |
TWI250978B true TWI250978B (en) | 2006-03-11 |
Family
ID=90001540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092104743A TWI250978B (en) | 2002-03-06 | 2003-03-06 | New compounds |
Country Status (28)
Country | Link |
---|---|
US (3) | US7348327B2 (zh) |
EP (1) | EP1487807B1 (zh) |
JP (1) | JP4559737B2 (zh) |
KR (1) | KR100977898B1 (zh) |
CN (2) | CN1639159A (zh) |
AR (1) | AR038868A1 (zh) |
AT (1) | ATE443054T1 (zh) |
AU (1) | AU2003209514B2 (zh) |
BR (1) | BR0307960A (zh) |
CA (1) | CA2475312C (zh) |
DE (1) | DE60329282D1 (zh) |
EA (1) | EA007410B1 (zh) |
EC (1) | ECSP045274A (zh) |
HR (1) | HRP20040910A2 (zh) |
HU (1) | HUP0200849A2 (zh) |
IL (2) | IL163286A (zh) |
IS (1) | IS7434A (zh) |
MA (1) | MA27105A1 (zh) |
MX (1) | MXPA04008613A (zh) |
NO (1) | NO20044221L (zh) |
NZ (1) | NZ535662A (zh) |
PL (1) | PL371099A1 (zh) |
RS (1) | RS79004A (zh) |
TN (1) | TNSN04141A1 (zh) |
TW (1) | TWI250978B (zh) |
UA (1) | UA78291C2 (zh) |
WO (1) | WO2003074500A2 (zh) |
ZA (1) | ZA200406467B (zh) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2291477T3 (es) * | 2001-06-27 | 2008-03-01 | Smithkline Beecham Corporation | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. |
HUP0202001A2 (hu) * | 2002-06-14 | 2005-08-29 | Sanofi-Aventis | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok |
TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE602004026289D1 (de) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
HU227684B1 (en) * | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
ZA200603165B (en) | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
KR20120008093A (ko) | 2003-11-17 | 2012-01-25 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
LT3366283T (lt) | 2004-01-20 | 2021-12-10 | Novartis Ag | Tiesioginio presavimo formulė ir procesas |
SI1712547T1 (sl) | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Bicikloestrski derivat |
CN1918131B (zh) | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶抑制剂 |
FR2870538B1 (fr) * | 2004-05-19 | 2006-07-14 | Servier Lab | Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AP2007003973A0 (en) | 2004-10-12 | 2007-07-30 | Glenmark Pharmaceuticals Sa | Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
JP2008024592A (ja) * | 2005-01-28 | 2008-02-07 | Taisho Pharmaceut Co Ltd | シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法 |
CN101277949A (zh) | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | 二肽基肽酶-ⅳ抑制剂 |
CN101232873A (zh) * | 2005-08-11 | 2008-07-30 | 霍夫曼-拉罗奇有限公司 | 含有dpp-iv抑制剂的药物组合物 |
MY147393A (en) | 2005-09-14 | 2012-11-30 | Takeda Pharmaceutical | Administration of dipeptidyl peptidase inhibitors |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US20090156465A1 (en) | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
AU2007224066B2 (en) | 2006-03-08 | 2011-10-27 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
CN101050194B (zh) * | 2006-04-05 | 2013-08-21 | 上海恒瑞医药有限公司 | 双环辛烷类衍生物、其制备方法及其在医药上的用途 |
MEP27308A (en) * | 2006-04-11 | 2010-06-10 | Arena Pharm Inc | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
CN101230059B (zh) * | 2007-01-23 | 2011-08-17 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
CN101230058A (zh) * | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
JPWO2008114857A1 (ja) | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
GB0713602D0 (en) * | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US8338450B2 (en) * | 2007-09-21 | 2012-12-25 | Lupin Limited | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
EP2246347B1 (en) * | 2008-01-23 | 2016-09-28 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Dicycloazaalkane derivates, preparation processes and medical uses thereof |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US8476470B2 (en) * | 2008-08-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
CN102186474A (zh) * | 2008-08-14 | 2011-09-14 | 杏林制药株式会社 | 稳定的医药组合物 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
WO2010054183A2 (en) * | 2008-11-07 | 2010-05-14 | President And Fellows Of Harvard College | Dyes, compositions and related methods of use |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
BRPI0923051B1 (pt) | 2008-12-19 | 2022-07-19 | Centrexion Therapeutics Corporation | Pirimidin-4-carboxamidas cíclicas como antagonistas do receptor de ccr2 para o tratamento de inflamação, asma e copd, seu uso, formulação e combinação farmacêutica que os compreende |
GB2483614B (en) | 2009-06-18 | 2014-12-03 | Lupin Ltd | 2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
EP2470552B1 (en) | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
KR101530234B1 (ko) | 2009-12-17 | 2015-06-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 신규한 ccr2 수용체 길항제 및 이의 용도 |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
EP2556056A1 (en) | 2010-04-06 | 2013-02-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
JP5646736B2 (ja) | 2010-05-12 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用 |
EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
WO2011144501A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
JP5636094B2 (ja) | 2010-05-25 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2受容体アンタゴニスト |
JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2アンタゴニスト |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013170115A1 (en) * | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Pyridazine and pyridine derivatives as nampt inhibitors |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US9567300B2 (en) | 2012-06-25 | 2017-02-14 | Sunshine Lake Pharma Co., Ltd. | Hexahydropentaleno derivatives, preparation method and use in medicine thereof |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
EP3085700B1 (en) | 2013-12-20 | 2018-10-31 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Novel piperidine carboxamide compound, preparation method, and usage thereof |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
CN104529856A (zh) * | 2015-01-13 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 一种硝基金刚烷酰胺衍生物、其制备方法和用途 |
CN104529858A (zh) * | 2015-01-13 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 含卤代金刚烷和酰胺类衍生物、其制备方法和用途 |
EP3053577A1 (en) * | 2015-02-09 | 2016-08-10 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
JP6772430B2 (ja) | 2015-03-03 | 2020-10-21 | サニオナ・エー/エス | テソフェンシンとベータブロッカーの合剤 |
KR20220070057A (ko) | 2015-03-09 | 2022-05-27 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
CN108026087B (zh) | 2015-07-02 | 2021-06-04 | 中枢疗法公司 | 氨基嘧啶甲酮衍生物的柠檬酸盐 |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのPPARγアゴニスト |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
AU2018386298B2 (en) | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2005A (en) * | 1841-03-16 | Improvement in the manner of constructing molds for casting butt-hinges | ||
US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
US3225037A (en) * | 1959-03-30 | 1965-12-21 | Sterling Drug Inc | 10-[(amino- and acylamino-1-piperidyl) lower-alkyl]-phenothiazines |
GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
US4302455A (en) * | 1980-04-14 | 1981-11-24 | Merck & Co., Inc. | 2-(4-Aminopiperidino)pyrazines |
US5001125A (en) | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
JP2869561B2 (ja) * | 1989-05-22 | 1999-03-10 | 大塚製薬株式会社 | 血小板粘着抑制剤 |
CA2106840A1 (en) * | 1992-09-25 | 1994-03-26 | Marco Baroni | Heteroarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them |
ES2079323B1 (es) * | 1994-06-21 | 1996-10-16 | Vita Invest Sa | Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes. |
UA51716C2 (uk) * | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
FR2780057B1 (fr) * | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
EP1178982B1 (en) * | 1999-05-21 | 2004-06-30 | Abbott Laboratories | Heterocyclic substituted aminoazacycles useful as central nervous system agents |
TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
NZ524618A (en) | 2000-08-10 | 2004-08-27 | Mitsubishi Pharma Corp | Proline derivatives and use thereof as drugs |
DE60135764D1 (de) | 2000-10-06 | 2008-10-23 | Mitsubishi Tanabe Pharma Corp | Stickstoffhaltige, fünfgliedrige ringverbindungen |
TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
JP2002264450A (ja) * | 2000-12-21 | 2002-09-18 | Ricoh Co Ltd | 画像処理ユニット、画像形成装置、画像形成方法及び画像処理システム |
EP1354882A1 (en) * | 2000-12-27 | 2003-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
GB0115517D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
ES2291477T3 (es) * | 2001-06-27 | 2008-03-01 | Smithkline Beecham Corporation | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. |
ES2339813T3 (es) * | 2001-06-27 | 2010-05-25 | Glaxosmithkline Llc | Fluoropirrolidinas como inhibidores de dipeptidil peptidasas. |
AU2003279368A1 (en) | 2002-06-20 | 2004-01-06 | Akzo Nobel N.V. | (stabilised) peroxide compositions phlegmatised with a specific unsaturated phlegmatising agent |
TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
CN1706726A (zh) * | 2004-02-17 | 2005-12-14 | 梅加特雷德国际公司 | 带发光部件的容器 |
-
2002
- 2002-03-06 HU HU0200849A patent/HUP0200849A2/hu unknown
-
2003
- 2003-03-04 NZ NZ535662A patent/NZ535662A/en unknown
- 2003-03-04 WO PCT/HU2003/000017 patent/WO2003074500A2/en active Application Filing
- 2003-03-04 AT AT03743452T patent/ATE443054T1/de not_active IP Right Cessation
- 2003-03-04 PL PL03371099A patent/PL371099A1/xx not_active Application Discontinuation
- 2003-03-04 RS YU79004A patent/RS79004A/sr unknown
- 2003-03-04 US US10/507,005 patent/US7348327B2/en not_active Expired - Fee Related
- 2003-03-04 EA EA200401157A patent/EA007410B1/ru not_active IP Right Cessation
- 2003-03-04 CN CNA038052636A patent/CN1639159A/zh active Pending
- 2003-03-04 CN CNA2006101640208A patent/CN1990486A/zh active Pending
- 2003-03-04 BR BR0307960-0A patent/BR0307960A/pt not_active IP Right Cessation
- 2003-03-04 CA CA2475312A patent/CA2475312C/en not_active Expired - Fee Related
- 2003-03-04 DE DE60329282T patent/DE60329282D1/de not_active Expired - Lifetime
- 2003-03-04 AU AU2003209514A patent/AU2003209514B2/en not_active Ceased
- 2003-03-04 JP JP2003572969A patent/JP4559737B2/ja not_active Expired - Fee Related
- 2003-03-04 MX MXPA04008613A patent/MXPA04008613A/es active IP Right Grant
- 2003-03-04 EP EP03743452A patent/EP1487807B1/en not_active Expired - Lifetime
- 2003-03-04 KR KR1020047013870A patent/KR100977898B1/ko not_active IP Right Cessation
- 2003-03-05 AR ARP030100723A patent/AR038868A1/es unknown
- 2003-03-06 TW TW092104743A patent/TWI250978B/zh not_active IP Right Cessation
- 2003-04-03 UA UA20041008080A patent/UA78291C2/uk unknown
-
2004
- 2004-07-29 IL IL163286A patent/IL163286A/en not_active IP Right Cessation
- 2004-07-29 MA MA27806A patent/MA27105A1/fr unknown
- 2004-07-29 TN TNP2004000141A patent/TNSN04141A1/en unknown
- 2004-08-13 ZA ZA200406467A patent/ZA200406467B/en unknown
- 2004-09-02 IS IS7434A patent/IS7434A/is unknown
- 2004-09-03 EC EC2004005274A patent/ECSP045274A/es unknown
- 2004-10-04 HR HR20040910A patent/HRP20040910A2/hr not_active Application Discontinuation
- 2004-10-05 NO NO20044221A patent/NO20044221L/no not_active Application Discontinuation
-
2006
- 2006-09-07 IL IL177933A patent/IL177933A0/en unknown
-
2008
- 2008-03-05 US US12/042,595 patent/US7655663B2/en not_active Expired - Fee Related
-
2010
- 2010-02-01 US US12/697,762 patent/US8063045B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI250978B (en) | New compounds | |
AU744411B2 (en) | 2-substituted 4,5-diaryl imidazoles | |
TWI344955B (en) | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient | |
CA3076022C (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
US20110021467A1 (en) | Indazolecarboxamide derivatives for the treatment and prevention of malaria | |
BR112019019017A2 (pt) | compostos heterocíclicos de utilidade como inibidores duplos de atx/ca | |
EA008166B1 (ru) | Производные азобициклооктанов и нонанов, обладающие активностью в ингибировании dpp-iv | |
CA2863517C (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
KR20150018788A (ko) | 혈전색전성 질환의 치료를 위한 인자 xia 억제제로서 치환된 피롤리딘 | |
US10501440B2 (en) | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | |
CN114478485B (zh) | 作为vanin抑制剂的杂芳族化合物 | |
US6903117B2 (en) | Indole derivatives for the treatment of osteoporosis | |
EP0802902A1 (en) | Indole derivatives useful in the treatment of osteoporosis | |
MXPA97006605A (en) | Indol derivatives as antagonists of amino acids exited | |
TW202023550A (zh) | 作為vanin抑制劑之雜芳族化合物 | |
JP2018510131A (ja) | Rorc2のスルホンアミド置換インドールモジュレーターおよびその使用方法 | |
KR102228034B1 (ko) | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 | |
JPWO2005030773A1 (ja) | 新規ピラゾロピリミジン誘導体 | |
JP2015527378A (ja) | Lpar置換シアノピラゾール化合物 | |
EP3801494A1 (en) | Antibacterial agents: dual-targeted rna polymerase inhibitors | |
ES2198319T3 (es) | Compuestos de pirrolopiridacina opticamente activos. | |
JPH0639471B2 (ja) | 抗潰瘍性(アルキルジチオ)キノリン誘導体 | |
CA2564668A1 (en) | Pyrrolidine derivatives | |
JP2019522651A (ja) | タンパク質キナーゼ阻害剤としての置換されているピロロ[2,3−d]ピリダジン−4−オン及びピラゾロ[3,4−d]ピリダジン−4−オン | |
FR2995605A1 (fr) | Derives de macrolides, leur preparation et leur application therapeutique. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |